AngioDynamics Director Vincent Bucci Purchases 5,000 Shares (ANGO)
AngioDynamics (NASDAQ:ANGO) Director Vincent Bucci acquired 5,000 shares of the stock on the open market in a transaction that occurred on Friday, October 18th. The shares were purchased at an average cost of $15.20 per share, with a total value of $76,000.00. Following the purchase, the director now directly owns 86,696 shares of the company’s stock, valued at approximately $1,317,779. The purchase was disclosed in a filing with the SEC, which can be accessed through this link.
Shares of AngioDynamics (NASDAQ:ANGO) traded up 0.43% on Monday, hitting $15.315. 119,527 shares of the company’s stock traded hands. AngioDynamics has a 52 week low of $9.52 and a 52 week high of $15.36. The stock has a 50-day moving average of $12.81 and a 200-day moving average of $11.51. The company’s market cap is $537.4 million.
AngioDynamics (NASDAQ:ANGO) last released its earnings data on Thursday, October 10th. The company reported $0.04 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.03 by $0.01. The company had revenue of $83.60 million for the quarter, compared to the consensus estimate of $82.54 million. During the same quarter in the prior year, the company posted $0.10 earnings per share. The company’s quarterly revenue was up .2% on a year-over-year basis. On average, analysts predict that AngioDynamics will post $0.34 earnings per share for the current fiscal year.
A number of research firms have recently commented on ANGO. Analysts at Canaccord Genuity raised their price target on shares of AngioDynamics from $11.50 to $13.00 in a research note to investors on Friday, October 11th. They now have a “hold” rating on the stock. Analysts at Zacks reiterated a “neutral” rating on shares of AngioDynamics in a research note to investors on Tuesday, October 1st. They now have a $14.00 price target on the stock.
AngioDynamics, Inc designs manufacture and sell a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.